Luca Sala

List of Publications by Year
in descending order

35 papers	1,610 citations	489802 18 h-index	591227 27 g-index
40 all docs	40 docs citations	40 times ranked	2626 citing authors

#	Article	IF	Citations
1	MTMR4 SNVs modulate ion channel degradation and clinical severity in congenital long QT syndrome: insights in the mechanism of action of protective modifier genes. Cardiovascular Research, 2021, 117, 767-779.	1.8	34
2	Precision Medicine and cardiac channelopathies: when dreams meet reality. European Heart Journal, 2021, 42, 1661-1675.	1.0	34
3	Estimating the Posttest Probability of Long QT Syndrome Diagnosis for Rare KCNH2 Variants. Circulation Genomic and Precision Medicine, 2021, 14, e003289.	1.6	10
4	Cardiac microtissues from human pluripotent stem cells recapitulate the phenotype of long-QT syndrome. Biochemical and Biophysical Research Communications, 2021, 572, 118-124.	1.0	8
5	Use of hiPSC-Derived Cardiomyocytes to Rule Out Proarrhythmic Effects of Drugs: The Case of Hydroxychloroquine in COVID-19. Frontiers in Physiology, 2021, 12, 730127.	1.3	4
6	Isogenic Sets of hiPSC-CMs Harboring Distinct KCNH2 Mutations Differ Functionally and in Susceptibility to Drug-Induced Arrhythmias. Stem Cell Reports, 2020, 15, 1127-1139.	2.3	23
7	Human-iPSC-Derived Cardiac Stromal Cells Enhance Maturation in 3D Cardiac Microtissues and Reveal Non-cardiomyocyte Contributions to Heart Disease. Cell Stem Cell, 2020, 26, 862-879.e11.	5.2	337
8	Cardiac Repolarization and Stem Cells: An Emerging Path Toward Precision Medicine. , 2020, , 87-107.		1
9	Simultaneous measurement of excitation-contraction coupling parameters identifies mechanisms underlying contractile responses of hiPSC-derived cardiomyocytes. Nature Communications, 2019, 10, 4325.	5.8	51
10	From patient-specific induced pluripotent stem cells to clinical translation in long QT syndrome Type 2. European Heart Journal, 2019, 40, 1832-1836.	1.0	69
11	Precision Versus Traditional Medicineâ€"Clinical Questions Trigger Progress in Basic Science. Circulation Research, 2019, 124, 459-461.	2.0	5
12	Long QT Syndrome Modelling with Cardiomyocytes Derived from Human-induced Pluripotent Stem Cells. Arrhythmia and Electrophysiology Review, 2019, 8, 105-110.	1.3	36
13	MUSCLEMOTION. Circulation Research, 2018, 122, e5-e16.	2.0	235
14	Action potential contour contributes to species differences in repolarization response to Î²-adrenergic stimulation. Europace, 2018, 20, 1543-1552.	0.7	22
15	Calmodulinopathy: A Novel, Life-Threatening Clinical Entity Affecting the Young. Frontiers in Cardiovascular Medicine, 2018, 5, 175.	1.1	25
16	Calmodulinopathy: Functional Effects of CALM Mutations and Their Relationship With Clinical Phenotypes. Frontiers in Cardiovascular Medicine, 2018, 5, 176.	1.1	19
17	Quantification of Muscle Contraction In Vitro and In Vivo Using MUSCLEMOTION Software: From Stem Cellâ€Derived Cardiomyocytes to Zebrafish and Human Hearts. Current Protocols in Human Genetics, 2018, 99, e67.	3.5	14
18	Three-dimensional cardiac microtissues composed of cardiomyocytes and endothelial cells co-differentiated from human pluripotent stem cells. Development (Cambridge), 2017, 144, 1008-1017.	1.2	216

#	Article	IF	Citations
19	Electrophysiological Analysis of human Pluripotent Stem Cell-derived Cardiomyocytes (hPSC-CMs) Using Multi-electrode Arrays (MEAs). Journal of Visualized Experiments, 2017, , .	0.2	27
20	Integrating cardiomyocytes from human pluripotent stem cells in safety pharmacology: has the time come?. British Journal of Pharmacology, 2017, 174, 3749-3765.	2.7	104
21	Elucidating arrhythmogenic mechanisms of long-QT syndrome CALM1-F142L mutation in patient-specific induced pluripotent stem cell-derived cardiomyocytes. Cardiovascular Research, 2017, 113, 531-541.	1.8	110
22	Integrating cardiomyocytes from human pluripotent stem cells in safety pharmacology: has the time come?. , 2017, 174, 3749.		1
23	A new <scp>hERG</scp> allosteric modulator rescues genetic and drugâ€induced longâ€<scp>QT</scp> syndrome phenotypes in cardiomyocytes from isogenic pairs of patient induced pluripotent stem cells. EMBO Molecular Medicine, 2016, 8, 1065-1081.	3.3	77
24	Human Induced Pluripotent Stem Cells-Derived Cardiomyocytes Carrying CALM1-F142l Mutation Recapitulate LQTS Phenotype in Vitro. Biophysical Journal, 2016, 110, 263a.	0.2	0
25	Late sodium current (INaL) in pancreatic Î²-cells. Pflugers Archiv European Journal of Physiology, 2015, 467, 1757-1768.	1.3	12
26	I _{Kr} Impact on Repolarization and Its Variability Assessed by Dynamic Clamp. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 1265-1275.	2.1	33
27	Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension. Cardiovascular Research, 2014, 104, 37-48.	1.8	42
28	Inal in the Pathophysiology of Insulin-Secretion: A â€œCardiacâ€•Paradigm in a New Cell Type. Biophysical Journal, 2014, 106, 327a.	0.2	0
29	Ikr Impact on Repolarization and its Variability Assessed by Dynamic-Clamp. Biophysical Journal, 2014, 106, 121a.	0.2	0
30	Genotype-Phenotype Correlation in Induced Pluripotent Stem Cell (iPSC)Derived Cardiomyocytes Carrying Calmodulin Mutations. Biophysical Journal, 2014, 106, 333a.	0.2	1
31	Action Potential Shape Differences Set Species-Dependent Î²-Adrenergic-Stimulation Response. Biophysical Journal, 2014, 106, 119a.	0.2	0
32	Altered functional differentiation of mesoangioblasts in a genetic myopathy. Journal of Cellular and Molecular Medicine, 2013, 17, 419-428.	1.6	3
33	Post-natal cardiomyocytes can generate iPS cells with an enhanced capacity toward cardiomyogenic re-differentation. Cell Death and Differentiation, 2012, 19, 1162-1174.	5.0	55
34	Aberrant Functional Differentiation of Cardiac Precursors from a Dystrophic Mouse. Biophysical Journal, 2012, 102, 674a.	0.2	0
35	Prevention of Myocardial Remodeling by Chronic INaL Blockade in Pulmonary Hypertension. Biophysical Journal, 2012, 102, 340a.	0.2	0